https://www.verahealth.ai/news/ros1-positive-nsclc-taletrectinib-approved-with-high-response-rates-in-tki-naive
ROS1-positive NSCLC: taletrectinib approved with high response rates in TKI-naive and pretreated...
FDA approval is based on two multicenter single-arm trials totaling 270 patients, showing ORR 85% to 90% in ROS1 TKI-naive and 52% to 62% after prior ROS1 TKI,...
positivensclctaletrectinibapprovedhigh